Hyperglycemia, diabetes, and de novo diabetes in patients hospitalized in intensive care units for COVID-19 in Colombia: Results from a longitudinal cohort study
, , , , , , and
Jul 31, 2025
About this article
Article Category: Research Article
Published Online: Jul 31, 2025
Page range: 257 - 264
Received: Jun 10, 2024
Accepted: Jun 05, 2025
DOI: https://doi.org/10.2478/jccm-2025-0026
Keywords
© 2025 John Jaime Sprockel et al., published by Sciendo
This work is licensed under the Creative Commons Attribution 4.0 International License.
Fig. 1.
Fig. 2.
Fig. 3.
Laboratory Results and Outcomes
| White blood cell count (×103 cells/μL) | 11894 (9607) | 11894 (9607) | 11911 (9685) | 11870 (9670) |
| Lymphocytes (×103 cells/μL) | 982 (1626) | 905 (772) | 867 (724) | 899 (785) |
| Platelet count (×103 cells/μL) | 241723 (95848) | 241723 (95848) | 242059 (95948) | 241986 (96157) |
| Lactate (mmol/L) | 1.96 (1.78) | 1.96 (1.78) | 1.98 (1.79) | 1.96 (1.79) |
| Creatinin (mg/dL) | 0.28 (0.73) | 0.27 (0.73) | 0.29 (0.74) | 2.0 (0.74) |
| Aspartate aminotransferase (U/L) | 126 (424.8) | 126 (424.8) | 127 (429.12) | 126 (428.4) |
| Alanine aminotransferase (U/L) | 97 (235.62) | 97 (235.62) | 98 (237.91) | 93 (208.2) |
| Prothrombin time (seg) | 12 (9.13) | 12 (9.13) | 12 (9.22) | 12 (9.21) |
| Partial thromboplastin time (seg) | 28.2 (17.7) | 28.2 (17.7) | 28.2 (17.92) | 28.3 (17.92) |
| C-reactive protein (mg/L) | 18.3 (20.21) | 18.3 (20.21) | 18.4 (20.36) | 18.4 (20.34) |
| Ferritin (ng/mL) | 1054 (635.43) | 1054 (635.43) | 1058 (628.93) | 1052 (635.49) |
| D – Dimer (μg/mL) | 220 (2100) | 220 (2100) | 224 (2122) | 224 (2122) |
| Lactate dehydrogenase, U/L | 1163 (5530) | 1163 (5530) | 1163 (5582) | 1167 (5568) |
| Positive troponin, n(%) | 257 (47.0%) | 172 (50.0%) | 49 (37.0%) | 36 (54.0%) |
| PaO2/FiO2 Ratio | 103 (61.41) | 103 (61.41) | 104 (61.77) | 103 (61.68) |
| Acute Physiology And Chronic Health | ||||
| Evaluation (APACHE) II at admission | 14.58 (7.16) | 14.58 (7.16) | 14.62 (7.17) | 14.56 (7.13) |
| Sequential Organ Failure Assessment (SOFA) at admission | 5.22 (3.55) | 5.22 (3.55) | 5.21 (3.57) | 5.22 (3.54) |
| CURB-65 | 1.82 (1.03) | 1.82 (1.03) | 1.82 (1.04) | 1.81 (1.03) |
| Severe ARDS (Pa/FiO2 <100) | 341 (62.34%) | 259 (75.0%) | 77 (58.0%) | 50 (75.0%) |
| Acute Liver Injury | 60 (10.96%) | 53 (15.2%) | 7 (5.3%) | 11 (16.4%) |
| Coagulopathy | 59 (10.78%) | 46 (13.31%) | 12 (9.0%) | 13 (19.4%) |
| CNS Involvement | 50 (9.14) | 37 (11.0%) | 12 (9.0%) | 12 (18.0%) |
| Acute Myocardial Injury | 141 (25.77) | 108 (31.1%) | 30 (23.0%) | 23 (34.3%) |
| Pulmonary embolism, n (%) | 65 (11.88%) | 51 (15.0%) | 13 (10.0%) | 17 (25.3%) |
| Length of Hospital Stay, mean (SD) | 23.6 (18.45) | 23.6 (18.45) | 23.75 (18.58) | 23.68 (18.56) |
| Death, n (%) | 317 (58.0%) | 211 (61.0%) | 65 (49.0%) | 41 (61.2%) |
Results of Bivariate Analyses
| All diabetes | 0.888 | 0.6953 – 1.135 | 0.344 |
| History of diabetes | 0.881 | 0.6675 – 1.163 | 0.371 |
| 0.963 | 0.672 – 1.378 | 0.835 |
General characteristics of the population
| Female sex, n (%) | 196 (36%) | 130 (37.5%) | 62 (46.7%) | 25 (37.3%) |
| Age (years), mean (SD) | 59.8 (14.3) | 59.83 (17.0) | 60.2 (13.9) | 59.6 (14.2) |
| 20–29, n (%) | 19 (3.4%) | 17 (4.8%) | 3 (2.3%) | 3 (4.5%) |
| 30–39 | 36 (6.5%) | 29 (8.3%) | 7 (5.2%) | 3 (4.5%) |
| 40–49 | 76 (13.9%) | 65 (18.7%) | 9 (6.8%) | 7 (10.5%) |
| 50–59 | 112 (20.4%) | 84 (24.2%) | 25 (18.8%) | 19 (28.3%) |
| 60–69 | 154 (28.1%) | 103 (29.6%) | 49 (36.8%) | 26 (39.0%) |
| 70–79 | 112 (20.4%) | 77 (22.2%) | 31 (23.3%) | 15 (22.4%) |
| 80–89 | 37 (6.7%) | 28 (8.06%) | 9 (6.8%) | 4 (6.0%) |
| <=90 | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Obesity, n (%) | 154 (28.1%) | 112 (32.3%) | 41 (30.8%) | 20 (30.0%) |
| Hypertension | 237 (43.3%) | 140 (40.3%) | 93 (70.0%) | 28 (42.0%) |
| Chronic Heart Disease (excluding Hypertension) | 60 (19.9%) | 38 (11.0%) | 22 (16.5%) | 8 (12.0%) |
| Chronic kidney disease | 22 (4.0%) | 11 (3.2%) | 11 (8.3%) | 1 (1.5%) |
| Smoking | 131 (23.9%) | 99 (28.5%) | 31 (23.3%) | 13 (19.4%) |
| Chronic lung disease | 107 (19.5%) | 72 (20.7%) | 34 (25.6%) | 14 (21.0%) |
| Chronic Neurological Disease or Dementia | 25 (4.5%) | 16 (4.6%) | 9 (6.8%) | 3 (4.5%) |
| Human Immunodeficiency Virus | 1 (0.18%) | 1 (0.3%) | 0 (0%) | 0 (0%) |
| Autoimmune disease | 6 (1.09%) | 6 (1.7%) | 0 (0%) | 0 (0%) |
| Cancer | 15 (2.74%) | 9 (2.6%) | 6 (4.5%) | 3 (4.5%) |
| Chronic liver disease | 6 (1.09%) | 5 (1.5%) | 1 (0.8%) | 1 (1.5%) |
| Symptom duration before ICU (days), mean (SD) | 8 (4.23) | 8 (4.23) | 8 (4.13) | 8 (4.23) |